Brief: Rg6501 (Opregen®) Phase 1/2A Results Show Evidence Of Rapid Improvement Of Outer Retinal Structure
05/10/2023 13:14
Oct 5 (Reuters) - Lineage Cell Therapeutics Inc
LCTX.A :
* RG6501 (OPREGEN®) PHASE 1/2A RESULTS SHOW EVIDENCE OF
RAPID
IMPROVEMENT OF OUTER RETINAL STRUCTURE IN PATIENTS WITH
GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nBw50GBf5a
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million